DexCom (DXCM) Reports New Clinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East escalations lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
October 2, 2023 2:00 AM EDTCOMISAIR study is now the longest prospective real-world CGM study ever conducted, demonstrating significant and continued HbA1c reduction for patients using real-time CGM over seven years.1 New data shows the Dexcom ONE CGM system delivers a clinically meaningful increase in time in range, reduction in HbA1c and improved glucose control for users with Type 2 diabetes.2 Based on a recent study of 96 pregnant women presented at EASD 2023, Dexcom G7 and Dexcom G6 are now the only commercially available CGM systems with clinical studies demonstrating real-time CGM is accurate for use... More
